Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis

Tuberculosis

Volumn 94, Issue 6, 2014, Pages 678-689

  Lan, Yun ^a   Lam, Jason T ^b   Siu, Gilman K H ^c   Yam, Wing Cheong ^b   Mason, A James ^d   Lam, Jenny K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antimicrobial peptides; Clinical isolates; Isoniazid; Multi drug resistant; THP 1; Tuberculosis

Indexed keywords

AGAR; D LAK 120; D LAK 120 A; D LAK 120 AP13; D LAK 120 H; D LAK 120 HP13; D LAK 120 P13; DEXTRO AMINO ACID; ISONIAZID; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL AGGREGATION; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EC50; EX VIVO STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; MACROPHAGE; MTT ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; BACTERIAL COUNT; CELL CULTURE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; CELLS, CULTURED; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ISONIAZID; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84919460794     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.08.001     Document Type: Article

References (42)

1. WHO Global tuberculosis report 2013 Geneva, Switzerland 2012
2. Tuberculosis in the UK: 2013 report 2013 Health Protection Agency London, UK
3. M.J. Fenton, and M.W. Vermeulen Immunopathology of tuberculosis: roles of macrophages and monocytes Infect Immun 64 1996 683 690
4. M.S. Gomes, S. Paul, A.L. Moreira, R. Appelberg, M. Rabinovitch, and G. Kaplan Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages Infect Immun 67 1999 3199 3206
5. J. Pieters Mycobacterium tuberculosis and the macrophage: maintaining a balance Cell Host Microbe 3 2008 399 407
6. A. Welin, J. Raffetseder, D. Eklund, O. Stendahl, and M. Lerm Importance of phagosomal functionality for growth restriction of Mycobacterium tuberculosis in primary human macrophages J Innate Immun 3 2011 508 518
7. L.S. Vermeer, Y. Lan, V. Abbate, E. Ruh, T.T. Bui, and L.J. Wilkinson Conformational flexibility determines selectivity and antibacterial, antiplasmodial, and anticancer potency of cationic alpha-helical peptides J Biol Chem 287 2012 34120 34133
8. Z. Jiang, M.P. Higgins, J. Whitehurst, K.O. Kisich, M.I. Voskuil, and R.S. Hodges Anti-tuberculosis activity of alpha-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37 Protein Peptide Lett 18 2011 241 252
9. P. Mendez-Samperio Role of antimicrobial peptides in host defense against mycobacterial infections Peptides 29 2008 1836 1841
10. P.T. Liu, and R.L. Modlin Human macrophage host defense against Mycobacterium tuberculosis Curr Opin Immunol 20 2008 371 376
11. B.M. Peters, M.E. Shirtliff, and M.A. Jabra-Rizk Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 6 2010 e1001067
12. M. Zasloff Antimicrobial peptides of multicellular organisms Nature 415 2002 389 395
13. K.A. Brogden Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3 2005 238 250
14. M.N. Melo, R. Ferre, and M.A. Castanho Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations Nat Rev Microbiol 7 2009 245 250
15. P. Nicolas Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides FEBS J 276 2009 6483 6496
16. S.Y. Hong, J.E. Oh, and K.H. Lee Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide Biochem Pharmacol 58 1999 1775 1780
17. P. Grieco, A. Carotenuto, L. Auriemma, M.R. Saviello, P. Campiglia, and I.M. Gomez-Monterrey The effect of d-amino acid substitution on the selectivity of temporin L towards target cells: identification of a potent anti-Candida peptide Biochim Biophys Acta 1828 2013 652 660
18. Y.M. Song, S.T. Yang, S.S. Lim, Y. Kim, K.S. Hahm, and J.I. Kim Effects of L- or D-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic alpha-helical model peptide on structure and cell selectivity Biochem Biophys Res Commun 314 2004 615 621
19. S.T. Yang, J.Y. Lee, H.J. Kim, Y.J. Eu, S.Y. Shin, and K.S. Hahm Contribution of a central proline in model amphipathic alpha-helical peptides to self-association, interaction with phospholipids, and antimicrobial mode of action FEBS J 273 2006 4040 4054
20. L. Fattorini, R. Gennaro, M. Zanetti, D. Tan, L. Brunori, and F. Giannoni In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis Peptides 25 2004 1075 1077
21. A. Kalita, I. Verma, and G.K. Khuller Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy J Infect Dis 190 2004 1476 1480
22. J.M. Reyrat, and D. Kahn Mycobacterium smegmatis: an absurd model for tuberculosis? Trends Microbiol 9 2001 472 474
23. T.P. Stinear, T. Seemann, P.F. Harrison, G.A. Jenkin, J.K. Davies, and P.D. Johnson Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis Genome Res 18 2008 729 741
24. K.C. Wong, W.M. Leong, H.K. Law, K.F. Ip, J.T. Lam, and K.Y. Yuen Molecular characterization of clinical isolates of Mycobacterium tuberculosis and their association with phenotypic virulence in human macrophages Clin Vacc Immunol CVI 14 2007 1279 1284
25. V. Jarlier, and H. Nikaido Mycobacterial cell wall: structure and role in natural resistance to antibiotics FEMS Microbiol Lett 123 1994 11 18
26. A. Ortalo-Magne, A. Lemassu, M.A. Laneelle, F. Bardou, G. Silve, and P. Gounon Identification of the surface-exposed lipids on the cell envelopes of Mycobacterium tuberculosis and other mycobacterial species J Bacteriol 178 1996 456 461
27. P.R. Meyers, W.R. Bourn, L.M. Steyn, P.D. van Helden, A.D. Beyers, and G.D. Brown Novel method for rapid measurement of growth of mycobacteria in detergent-free media J Clin Microbiol 36 1998 2752 2754
28. S. Borrell, and S. Gagneux Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 13 2009 1456 1466
29. S. Ramaswamy, and J.M. Musser Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update Tuber Lung Dis Off J Int Union Against Tuberc Lung Dis 79 1998 3 29
30. G.E. Louw, R.M. Warren, N.C. Gey van Pittius, C.R. McEvoy, P.D. Van Helden, and T.C. Victor A balancing act: efflux/influx in mycobacterial drug resistance Antimicrob Agents Chemother 53 2009 3181 3189
31. S.E. Dorman, and R.E. Chaisson From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis Nat Med 13 2007 295 298
32. D. Kaur, M.E. Guerin, H. Skovierova, P.J. Brennan, and M. Jackson Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis Adv Appl Microbiol 69 2009 23 78
33. V. Borelli, F. Vita, S. Shankar, M.R. Soranzo, E. Banfi, and G. Scialino Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis Infect Immun 71 2003 605 613
34. W.A. Ernst, S. Thoma-Uszynski, R. Teitelbaum, C. Ko, D.A. Hanson, and C. Clayberger Granulysin, a T cell product, kills bacteria by altering membrane permeability J Immunol 165 2000 7102 7108
35. B. Rivas-Santiago, C.E. Rivas Santiago, J.E. Castaneda-Delgado, J.C. Leon-Contreras, R.E. Hancock, and R. Hernandez-Pando Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis Int J Antimicrob Agents 41 2013 143 148
36. A.A. Velayati, P. Farnia, T.A. Ibrahim, R.Z. Haroun, H.O. Kuan, and J. Ghanavi Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy Chemotherapy 55 2009 303 307
37. N. Rastogi, and K.S. Goh Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine Antimicrob Agents Chemother 34 1990 2061 2064
38. H. Ando, Y. Kondo, T. Suetake, E. Toyota, S. Kato, and T. Mori Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis Antimicrob Agents Chemother 54 2010 1793 1799
39. J.M. Musser, V. Kapur, D.L. Williams, B.N. Kreiswirth, D. van Soolingen, and J.D. van Embden Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance J Infect Dis 173 1996 196 202
40. H.S. Schaaf, T.C. Victor, E. Engelke, W. Brittle, B.J. Marais, and A.C. Hesseling Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 26 2007 203 205
41. S.K. Katiyar, S. Bihari, S. Prakash, M. Mamtani, and H. Kulkarni A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis 12 2008 139 145
42. J.A. Caminero, G. Sotgiu, A. Zumla, and G.B. Migliori Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis Lancet Infect Dis 10 2010 621 629